SIR-Spheres® Y-90 resin microspheres
About SIR-Spheres
SIR-Spheres Y-90 resin microspheres are a permanent implant and for single use only.
The high number of microspheres provides a uniform radiation distribution, enabling treatment of solitary and multifocal liver tumors.1–3
With a specific density close to that of red-blood cells,1 they are carried by the blood flow, penetrating deep into the tumor microvasculature.
SIR-Spheres can therefore be delivered in a slow, deliberate manner:
- to achieve an even distribution
- to maximize the number of microspheres delivered
- to optimize tumor coverage - even in patients with extensive disease
Yttrium-90 has two inherent safety features for staff and patients:
- the minimal penetration depth of beta radiation emissions through tissue and air
- the relatively short half-life of 64.1 hours
Product Features |
|
| Manufacturer | Sirtex Medical Pty Ltd |
| Isotope | Yttrium-90 |
| Decay product | Zirconium-90 |
| Composition | Resin (sulfonated divinyl benzene-styrene copolymer) |
| Specific density | 1.125-1.6 g/ml (comparable to red blood cells) |
| Diameter | 32±10 µm |
| T1/2 | 64.1 h (94% within 11 days) |
| Penetration in tissue | 2.5 mm (mean) |
| Presentation of activity | Single dose size containing 3.0 GBq ± 10% of Y-90 at calibration date & time in 5 ml water for injection, moist sterilized. |
| No. of microspheres per vial | 44 (± 2.6) million |
Additional Product Information
- Sirtex internal data
- Burrill J et al. J Nucl Med Radiat Ther 2011; 2:107. doi:10.4172/2155-9619.1000107.
- Chiesa et al. Q J Nucl Med Mol Imaging 2011; 55: 168–197.
SIR-Spheres® Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) or unresectable metastatic liver tumors from primary colorectal cancer (mCRC) in patients refractory to or intolerant of chemotherapy.
SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.